key: cord-0977629-knfmi3xa
authors: Malik, Salik; Kaushik, Chandani; Heidelman, Eric; Polychronopoulous, Efstathia; Kuo, Yong-Fang; Sharma, Gulshan; Nishi, Shawn P.E.
title: Characteristics and Factors Associated with Mortality in COVID-19 Patients with Pneumothorax
date: 2022-04-26
journal: Mayo Clin Proc Innov Qual Outcomes
DOI: 10.1016/j.mayocpiqo.2022.04.003
sha: 2d2280aeca6ad77a0123ee2a893048078b7171b7
doc_id: 977629
cord_uid: knfmi3xa

Objective To describe the incidence, clinical characteristics and factors associated with mortality of hospitalized patients with COVID-19 who developed pneumothorax. Patients and Methods This study was a retrospective analysis using a large administrative database of adult hospitalized patients with COVID-19 infection in the United States from February 1, 2020 to June 10, 2021. We characterize the clinical features of these patients that develop pneumothorax, the factors associated mortality, and also stratified pneumothorax by timing of invasive mechanical ventilation initiation (IMV) and by time from admission (early versus late). Results A total of 811,065 adult patients had a SARS-CoV-2 positive test and 103,858 (12.8%) were hospitalized. Pneumothorax occurred in 1,915 (0.24% overall, 1.84% among hospitalized). Over time, use of steroids and remdesivir increased. IMV use, pneumothorax rates and mortality decreased. Clinical characteristics associated with pneumothorax were male gender, receipt of IMV and treatment with steroids, remdesivir or convalescent plasma. Most patients with pneumothorax received IMV, but the majority developed pneumothorax prior to initiation of IMV and/or early in the hospitalization. Multivariable analysis showed pneumothorax increased the risk of death (adjusted Hazard Ratio [aHR] 1.15; 95% Confidence Interval [CI] 1.06-1.24). In patients who did not receive IMV, pneumothorax had nearly twice mortality (aHR 1.99; 95% CI 1.56-2.54). Increased mortality was also noted when pneumothorax occurred prior to IMV (aHR 1.37; 95% CI 1.11-1.69) and within 7 days of hospital admission (aHR 1.60; 95% CI 1.29-1.98). Conclusion The overall incidence of pneumothorax in hospitalized patients with COVID-19 infection was low. Pneumothorax is an independent risk factor for death.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged as a global pandemic March 11, 2020 and has caused, to date, over 50 million cases and an excess of 800,000 deaths in the United States (US) 1 . Coronavirus Disease 2019 , the infectious disease caused by the SARS-CoV-2 virus, is now the leading cause of death in the US in 2021 2 . Overall mortality rate is 1.6% 3 but increases to 4-23% with severe disease 4 (I.e., among hospitalized patients), and nearly 80% in those receiving invasive mechanical ventilation (IMV) 4 .

Pneumothorax is an increasingly reported complication of COVID-19 and may be a marker of disease severity. Radiologically, architectural distortion of the lung parenchyma with cyst formation has been shown in COVID-19 lungs which may predispose such patients to the development of pneumothorax 5 .

Clinically, patients with pneumothorax were shown to have inferior gas exchange and worse respiratory mechanics than those who did not have pneumothorax 6, 7 . The development of pneumothorax in patients with COVID-19 with severe respiratory illness may also be associated with increased mortality [8] [9] [10] . Management strategies, knowledge and treatment evolve as we learn more about SARS-CoV-2. For instance, clinical trials such as the RECOVERY and ACTT trials emerged within the initial year of the pandemic, demonstrated improved mortality and outcomes with dexamethasone and remdesivir treatment and are used as standard of care 11, 12 . Early proning and non-invasive ventilation (NIV) were increasingly employed to delay or avoid IMV 13 . Waves of disease characterized by a high incidence of cases lasting weeks until infection rates troughed also stressed resources such as staffing, supplies and space which, and new virus variants emerged 4 . These factors may alter the clinic course of disease and the development of pneumothorax and COVID-19 outcomes.

To date, little is known about the incidence, characteristics associated with developing pneumothorax or factors associated with poor outcomes of patients with COVID-19 and pneumothorax. Even less is known about how these changed over the course of the pandemic. Most information stems from: small case series; populations limited to critical illness or IMV use; reports from early in the pandemic when knowledge of SARS-CoV-2 and management options were limited; or series outside the US.

The purpose of this study was to examine hospitalized patients with COVID-19 who developed pneumothorax and describe the incidence, clinical characteristics for developing pneumothorax and factors associated with inpatient mortality. We further stratified the cohort by receipt of invasive mechanical ventilation, timing of pneumothorax and by wave of pandemic. The study was conducted using a retrospective cohort analysis of a large, nationally representative dataset in the US.

In this retrospective cohort study, we used Optum's longitudinal COVID-19 electronic health deidentified records database consisting of multiple hospital networks from all regions in the US consisting of >90 million patients. The database contains de-identified inpatient and ambulatory encounter-level information, as well as procedure, prescription and medication administration data. The University of Texas Medical Branch institutional review board approved this study (IRB# is 20-0180). Written informed consent was not required due to the de-identified nature of the patient data.

The study cohort included patients >18 years of age diagnosed with SARS-CoV-2 infection between February 1, 2020 and June 10, 2021 who were subsequently hospitalized within 14 days. COVID-19 was identified by a positive laboratory test for SARS-CoV-2 (e-Appendix 1) or by the International Classification for Diseases, tenth revision, clinical modification (ICD-10-CM) diagnosis code U07.1.

We collected information on patient demographics as well as clinical and medication history. ICD-10-PCS codes were used to identify convalescent plasma (XW13325, XW14325) and remdesivir (XW043E5, XW033E5) administered during hospitalization. Steroids were identified using National Drug Codes with product and therapeutic class names from the 2019 Red-book Select database (RED BOOK Select Extracts. Truven Health Analytics; 2019. Ann Arbor, MI). The primary outcome was inpatient mortality among patients with COVID-19-associated hospitalization. The main independent variable of interest was pneumothorax and was defined based on the ICD-10-CM diagnosis code J93.X. Among the subset of patients with pneumothorax, we defined early pneumothorax as occurring within 7 days from hospital admission. IMV use was based on ICD-10-PCS codes (5A1935Z, 5A1945Z, 5A1955Z) and Current Procedural Terminology code 31500.

Patient and clinical characteristics were summarized as frequencies and percentages or means and standard deviations, then compared using chi-square statistics or t-tests, as appropriate. A logistic regression model with random effect for hospital network was used to determine the predictors of being diagnosed with pneumothorax. We used time-dependent Nelson-Aalen cumulative hazard functions to assess the rate of inpatient mortality among patients with and without pneumothorax.

Multivariable Cox-proportional hazards models with random effects for hospital network were used to estimate hazards ratios for inpatient mortality accounting for patient and clinical characteristics.

Pneumothorax was included in the model as a time-dependent variable based on the date of onset.

Patients were censored at time of death, hospital discharge or the end of the study period (June 24, 2021). The interaction between pneumothorax and mechanical ventilation was also tested. Additionally, we conducted subset analyses among patients with pneumothorax to determine the effect of timing of presentation (early or late, before or after mechanical ventilation) on inpatient mortality. Multivariable Cox proportional hazards models were used to model these effects. All analyses were performed using SAS version 9.4 (SAS, Inc., Cary, NC, US). A P-value of <0.05 was considered statistically significant.

During the study period, 811,065 adults had a SARS-CoV-2 positive test and had complete data. Of these, 103,858 (12.8%) adult patients were hospitalized within 14 days of diagnosis. Pneumothorax occurred in 1,915 (0.24%) of those with a SARS-CoV-2 diagnosis and 1.84% of hospitalized COVID-19

patients. Of patients with pneumothorax, 70% required tube thoracostomy, and nearly 1/3 required insertion of more than 1 chest tube. Table 1 shows the characteristics of hospitalized COVID-19 patients. Overall, the average age was 62 years, gender was nearly equal, and over half were Caucasian. Smoking status, either current or prior smokers, accounted for 38% of the cohort and did not differ by pneumothorax status. By treatment, 15 .9% received IMV, few received convalescent plasma, 1/3 received remdesivir, and over half received steroids. When we compare characteristics by pneumothorax status, a higher proportion of pneumothorax occurred in those aged between 51-80 years and in males. Differences in race were observed overall and by pneumothorax status. For instance, similar proportions of Caucasians hospitalized by pneumothorax status were noted. African Americans accounted for 18.9% of COVID-19 hospitalizations but represented only 13.8% of those with a pneumothorax diagnosis. Whereas Hispanics and Asians comprised 12.4% and 2.5% of the cohort, respectively, both represented higher proportions of pneumothorax cases (15.1% and 3.7%, respectively). By treatment, a higher proportion of those with pneumothorax received IMV, remdesivir, convalescent plasma and steroids compared to those who did not have pneumothorax. Among those with pneumothorax, >80% occurred early i.e., within 7 days of hospitalization. Although the majority received IMV during hospitalization, more than three-quarters of those with pneumothorax developed their pneumothorax prior to IMV initiation.

Patients with pneumothorax were on average hospitalized longer (9 days v 23.2 days).

When we looked at patient characteristics and the outcomes of hospitalized patients by waves (e- Table   1) , changes were noted, mainly in treatment, with the use of remdesivir and steroids increasing significantly (from 0.3% to 44.1% and 30.6% to 61.4%, respectively). When looking at overall trends overtime, we excluded wave 4 as the study period may have ended before all patient outcomes were resolved. IMV use decreased from 21.3% in wave 1 to 15% by the wave 2 and then remained steady.

Pneumothorax rates overall remained stable but the proportion of pneumothorax who did not receive IMV or developed pneumothorax prior to IMV initiation increased. Overall mortality of the COVID-19 cohort was 11%. Mortality for all hospitalized COVID-19 patients decreased while mortality was stable over time in those with pneumothorax and in those who received IMV.

As shown in Table 2 , factors associated with increased odds for developing pneumothorax among hospitalized COVID-19 patients were male gender and age 51-80 years. Treatment with steroids, convalescent plasma and IMV showed increased odds ratio of being associated with pneumothorax.

Receipt of remdesivir showed no difference in the incidence of pneumothorax. Table 3 presents the multivariate analysis of the characteristics associated with inpatient death among patients hospitalized with COVID-19. The most significant risk factors associated with inpatient death were increasing age and receipt of IMV. In patients who developed pneumothorax, the hazard ratio of inpatient death was 1.15 (95% Confidence Interval [CI] 1.06-1.24). Patients who received remdesivir and steroids had a lower hazard of inpatient death.

Stepwise multivariate analysis (Figure 1 ) was conducted to show the impact on mortality of comorbidities, demographics and IMV use in those with pneumothorax. Patient demographics and comorbidity had the highest effect on increasing mortality, while receipt of IMV and medications attenuated this effect.

We also looked at the effect on mortality of the interactions of pneumothorax and IMV, and the effect of timing of pneumothorax. The risk of death was double when we compared those who never received IMV and who had pneumothorax to those who received IMV at some point during their hospitalization (adjusted Hazard Ratio [aHR] 1.99, 95% CI 1.56-2.54). Among patients who received IMV, the presence of pneumothorax increased the risk of death by 9% (aHR 1.09, 95% CI 1.0-1.19) (Figure 2 ). However, when we looked at the timing of pneumothorax -both before IMV initiation or early (within 7 days of admission) -we found an increased hazard of death after adjusting for all variables in Table 1 [(aHR 1.37, 95% CI 1.11-1.69) and (aHR 1.60, 95% CI 1.29-1.98), respectively] ( Figure 3 ).

In summary, we characterized and described outcomes among hospitalized patients with SARS-CoV-2 and pneumothorax in a large US cohort. The rate of pneumothorax was less than 2%. Risks for pneumothorax were age and male gender. Treatment with steroids, convalescent plasma and IMV were also shown to increase the hazard ratio for pneumothorax, but this association may reflect the severity of disease rather than a causal relationship. Pneumothorax is associated with increased risk of death, especially when it develops early and/or prior to IMV initiation, which occurred in the majority of these patients.

An interesting finding was the increased proportion (>2/3) of pneumothorax noted among males with COVID-19, also seen in multiple previous reports 6,7,14-16 . However, a similar proportion (77%) of pneumothorax among males was observed prior to SARS-CoV-2 17 . While the reasons for this are unknown, hypotheses include the increase prevalence of tobacco consumption and the anthropometric characteristics of males 17, 18 .

We noted that >80% of pneumothorax occurred in patients who never received IMV or in patients prior to IMV initiation. The reasons for this phenomenon are unclear. Increased use of positive pressure via expanded use of NIV 6, 7, 9, 19, 20 and prolonged duration of NIV prior to initiation of IMV 21 have both occurred during the pandemic and are also shown to increase incidence of barotrauma 15 . Unfortunately, NIV use could not be ascertained with our data, and it is unclear whether NIV as a risk for pneumothorax accounted for increased rates of pneumothorax.

Similar to our study, other reports showed that up to half of pneumothorax cases occurred while the patient was not receiving IMV 14, 15, 19, 20 . One of the largest studies of pneumothorax in COVID-19 reported that pneumothorax occurred while using simple low flow supplemental oxygen (31%) or no oxygen therapy (5%) 15 . Palumbo et al. showed that just under half of cases of pneumothorax occurred when using simple oxygen 22 . These reports may suggest pathophysiology beyond that caused solely by positive pressure ventilation.

One explanation may be the phenomenon known as the Macklin effect, where an increase pulmonary interstitial pressure above alveolar pressure along with sudden lengthening and shortening of the pulmonic vessels and associated bronchi prompts alveolar leakage along the vascular sheaths 23 . This can occur with increased work of breathing and coughing --predominant features with COVID-19. Another proposed mechanism involves a high respiratory drive, excessive inspiratory effort and uncontrolled transpulmonary pressures, causing patient self-inflicted lung injuries; however, this phenomenon remains controversial 24 .

Similar to our study, prior series of COVID-19 patients have also shown that pneumothorax independently carries up to three times the risk of death 6,7,16,25 . Our a priori hypothesis was that the development of pneumothorax increases mortality, which is further increased while receiving IMV.

Unexpectedly, our analysis in those with IMV showed that the effect of pneumothorax after adjusting for demographics and co-morbidities was marginally significant in predicting death. For patients without IMV, however, the effect of pneumothorax on mortality was significant. This result differs from those of prior reports; however, those studies included patients who first received IMV and subsequently develop pneumothorax or they did not mention the timing of pneumothorax relative to IMV initiation 6,16 . Rajdev et al. observed, among patients with COVID-19 hospitalized with pneumothorax or pneumomediastinum, an increased mortality in those with NIV v IMV (80% v 20%, respectively) 19 . We are unaware of any study evaluating the risk of pneumothorax or mortality specifically when pneumothorax develops before IMV. Reasons for an increased mortality in patients with pneumothorax not receiving IMV may be due to a high mortality rate before IMV initiation; under-recognition of pneumothorax needing decompression; or the fact that IMV after development of pneumothorax truly does not confer further increased risk of death in this population.

The largest prior US reports included <90 pneumothorax cases each from New York 6, 7, 25 A multi-center research letter recently published from the UK of 1,283 pneumothorax diagnosis in COVID-19 hospitalized patients during a similar time period used descriptive statistics to report the rates of pneumothorax and oxygen, IMV and steroid use 15 . The incidence of pneumothorax was less than half that reported in our study and the researchers found a higher --nearly three times --risk of death with pneumothorax 15 which did not change over the first half of the study period. The contribution of IMV or timing of pneumothorax to death were not reported. Comparison of our results to this study is difficult as it failed to report overall mortality, comorbidity, or trends over time. Also, the US had a disproportionate and early access to prevention, such as vaccinations and remdesivir, which were not readily available in the UK until recently, and these discrepancies may have affected disease severity and outcomes, especially during the first 2 waves.

This study is the largest cohort reported to date of pneumothorax in hospitalized COVID-19 patients. We examined the trends of patient characteristics and outcomes related to pneumothorax development by time. Further, we provided additional information by reporting timing of pneumothorax related to the hospitalization course, which has not been previously reported. Reporting time trends is important as our understanding of prevention, treatment, and the disease itself evolves, which may alter outcomes over time. For example, the incidence of vaccination, medications and treatment in the form of medications, proning and the use of NIV and IMV significantly changed over time, and these changes may account for differences in outcomes.

There are several limitations of our study. First, certain limitations are related to the retrospective observational nature of the study. Second, administrative data cannot differentiate types of barotrauma (pneumothorax v pneumomediastinum), unilateral from bilateral pneumothorax; primary spontaneous from secondary pneumothorax from iatrogenic; or pre-existing lung disease from COVID-19-related disease. Third, caution should be used when evaluating potential effects of smoking status which is found to be highly specific but <10% sensitivity that has not changed over time with the use of administrative datasets 26, 27 . Fourth, it is possible undiagnosed pneumothorax cases and their attributable deaths occurred, which would underreport the true rate of occurrence and attributable mortality. Further, we could not stratify patients by severity of respiratory parameters such as oxygenation or lung mechanics, nor could we determine if best practices that may affect outcome, such as lung protective ventilation strategies, were adhered to; however, prior reports examining this across the US have shown adherence to these best practices 6, 7 . Additionally, one publication showed no difference in tidal volume or peak airway pressures in COVID-19 patients receiving IMV between those with or without barotrauma 28 . We attempt to control for these variables by comparing patients with and without pneumothorax over the same time.

In summary, incidence of pneumothorax in patient hospitalized with COVID-19 is low. Most cases of patients with pneumothorax occurred early and prior to initiation of IMV. Risk for developing pneumothorax were age 50-80 years and male gender. Pneumothorax is an independent risk factor for death. 

Forrest plot for hazard ratios (HRs) and 95% Confidence Interval (CI) among patients hospitalized with COVID-19 with pneumothorax evaluating the effect of pneumothorax timing from February 2020 to June 2021 in the United States * . Definition of abbreviation: IMV: invasive mechanical ventilation

* HR adjusted for age, gender, race, region, comorbidities and treatments received, as listed in Table 1. REFERENCES 1. WHO Health Emergency Dashboard COVID-19: United States of America World Health Organization

COVID19 pneumonia with cavitation and cystic lung changes: multi-detector computed tomography spectrum of a gamut of etiologies

Pneumothorax in critically ill patients with COVID-19 infection: Incidence, clinical characteristics and outcomes in a case control multicenter study

Pneumothorax in COVID-19 Acute Respiratory Distress Syndrome: Case Series. Cureus

Pneumothorax in the intensive care unit: incidence, risk factors, and outcome

The incidence, clinical characteristics, and outcomes of pneumothorax in hospitalized COVID-19 patients: A systematic review. Heart Lung

Pneumothorax in COVID-19 disease-incidence and clinical characteristics

Dexamethasone in Hospitalized Patients with Covid-19

Remdesivir for the Treatment of Covid-19 -Final Report

High-Flow, Noninvasive Ventilation and Awake (Nonintubation) Proning in Patients With Coronavirus Disease

COVID-19 and pneumothorax: a multicentre retrospective case series

COVID-19 Pneumothorax in the United Kingdom: a prospective observational study using the ISARIC WHO clinical characterisation protocol

Outcomes of Barotrauma in Critically Ill COVID-19 Patients With Severe Pneumonia

Epidemiology of spontaneous pneumothorax: genderrelated differences

Independent risk factors for cumulative recurrence rate after first spontaneous pneumothorax

Pulmonary Barotrauma in COVID-19 Patients With ARDS on Invasive and Non-Invasive Positive Pressure Ventilation

Spontaneous pneumothorax: An emerging complication of COVID-19 pneumonia

Characteristics, outcomes and global trends of respiratory support in patients hospitalized with COVID-19 pneumonia: a scoping review

Pneumothorax/pneumomediastinum in nonintubated COVID-19 patients: Differences between first and second Italian pandemic wave

Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure

Increased Incidence of Barotrauma in Patients with COVID-19 on Invasive Mechanical Ventilation

Trends in tobacco use and tobacco cessation counselling codes among Medicare beneficiaries

Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke

High Incidence of Barotrauma in Patients With Severe Coronavirus Disease